OBILET
4.8.2021 11:02:07 CEST | Business Wire | Press release
obilet.com, Turkey’s premier online travel ticketing platform, is set to enjoy rapid growth in the wake of the Covid-19 pandemic. Having just acquired its arch-rival Biletall, Obilet is forecast to sell more than 20 million tickets in 2021 – up from 8 million in 2020 – and close out the year with $300 million GMV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005055/en/
Thanks to its unique offerings and innovative business model, the Istanbul-based travel-tech firm is now poised to expand its geographic reach amid an expected post-Covid global recovery.
SaaS-Powered Business Model
Already known throughout the region for its enormously popular ticket-booking app, Obilet’s primary distinction lies in its SaaS (Software-as-a-Service) powered business model. Obilet, invested in by EarlyBird and EBRD, provides bus operators with a best-in-class Ticket Management System (TMS) featuring 24/7 technical support. The company thereby creates a “lock-in effect” for its business operations on the supply side.
By distributing its portfolio of bus operators using its SaaS to other online ticketing platforms on a revenue-sharing basis, Obilet adds additional revenue streams on top of its lucrative B2C sales.
One of the world’s top-10 platforms for online bus and flight tickets, obilet.com saw remarkable growth in the pre-Covid-19 2016-2019 period, boasting a compound annual growth rate (CAGR) of 77%.
Biletall Buyout Cements Leading Position
Earlier last month (July 12), Obilet cemented its regional position by acquiring Biletall, its chief B2C and B2B competitor, which since the 2000s had played a pioneering role in the digitalization of Turkey’s travel industry. Although Obilet stole the top spot from Biletall in 2016 on the B2C side, Biletall nevertheless retained its leading position at B2B coverage.
The acquisition will give Obilet 100% destination coverage in one of the world’s largest bus markets, and the biggest in Europe. Turkey’s intra-state bus market currently generates some 200 million ticket sales per year, corresponding to roughly $3 billion annually.
Currently, more than 300 bus operators compete in this highly fragmented market, which remains largely unconsolidated despite the 2019 acquisition of the country’s largest domestic bus operator by Flix.
Plans for Expansion in Post-Covid Era
Obilet now is equipped with plug-and-play B2B and SaaS solutions to be offered to both operators and online/offline ticket resellers in neighboring countries, where there is huge revenue potential for the Turkish start-up.
Obilet’s vastly enhanced market share, coupled with rising travel demand in the post-Covid era, is expected to yield 40 million ticket sales in 2022 and a GMV of over $500 million. Company officials even suggest that, as Obilet gradually expands into fresh markets, annual GMV could reach as much as $1 billion within the next few years.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005055/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 22:00:00 CEST | Press release
Researchers across Asia-Pacific gain a new option for high-quality single cell sequencing through Garvan's Evercode WT services Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Ins
Grafana Labs Named a Leader in 2026 Gartner® Magic Quadrant™ for Observability Platforms and Positioned Furthest in Completeness of Vision15.7.2026 20:21:00 CEST | Press release
Named a Leader for the third consecutive year and placed furthest in vision for the second year in a row, the company has had a landmark year of innovation as observability becomes essential infrastructure for teams building and running AI at scale. Grafana Labs, the company behind the open observability cloud, today announced it has been named a Leader in the Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, and positioned furthest on the Completeness of Vision axis for the second year running. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715814984/en/ 2026 Gartner® Magic Quadrant™ for Observability Platforms We believe this placement reflects where the market is headed: toward open, composable observability that helps teams in the AI era understand systems that are increasingly complex and agentic, and rapidly scaling thanks to AI-assisted engineering. A Platform Built for the AI Era
Spectro Cloud Raises $100 Million Series D to Help Customers Move AI Infrastructure Into Production Across Enterprise, Public Sector, Neocloud and Sovereign Cloud Environments15.7.2026 18:20:00 CEST | Press release
Growth Equity at Goldman Sachs Alternatives leads oversubscribed round with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus as organizations look to turn AI silicon into business outcomes Spectro Cloud, a leading provider of AI infrastructure management software, today announced it has raised more than $100 million in an oversubscribed Series D funding round led by Growth Equity at Goldman Sachs Alternatives, with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus. The new funding brings Spectro Cloud’s total capital raised to $260 million and will accelerate the company’s mission to help enterprises, public sector organizations, neoclouds and sovereign clouds build and operate production AI infrastructure with greater control over cost, security and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715551858/en/ Spectro Cloud raises $
K-Beauty Goes Global: Sales Surge 53% as Korean Innovation Reshapes Beauty Growth15.7.2026 16:00:00 CEST | Press release
New NIQ data shows K-Beauty value sales rose 53% year-over-year and 131% over two years, underscoring how regional beauty trends, social commerce and ingredient-led innovation are reshaping global beauty growth. NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released new findings showing K-Beauty has become a rapidly growing global beauty segment, with value sales up 53% year-over-year and 131% over the past two years. The data points to a broader shift in beauty growth, as regional innovation, social commerce and digitally driven consumer demand increasingly shape what scales globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715867578/en/ K-Beauty accelerates across global markets In its latest report, K-Beauty Goes Global, NIQ shows how Korean beauty is reshaping consumer expectations, accelerating innovation cycles and redefining competitive dynamics across the global beauty market. What began
Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage15.7.2026 15:00:00 CEST | Press release
Viz Neuro™ Suite, including Viz ICH™ and Viz ICH Plus™, to facilitate rapid detection and care coordination for patients with basal ganglia hemorrhage across trial sites nationwide. Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to potentially improve functional patient outcomes. The study aims to initiate both randomization and surgical intervention within 120 minutes of key clinical time points, reflecting the urgent nature of intracerebral hemorrhage care. Participating sites will have the ability to leverage the Viz Neuro Suite platform, including Viz ICH and Viz ICH Plus, to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
